FAK inhibitors, alone or in combination with anti-cyclin-dependent kinase 4/6 (anti-CDK4/6) inhibitors, may be effective treatments for ICCA [75]. The gene discussed is PTK2; the disease is infantile convulsions and choreoathetosis.